N Drug Or Nan Composi Method Rout conclu Jour Yea Research DOI Stu

O ga ocar tion of of e of sion nal r of den

n rier system preparati admi Nam pub t
on nistr e licat Na
ation ion me

1 Nefo bra Nios Nefopa NF- Oral The Intra 17 10.2147/dddt. Ger
pam in ome m HCl loaded and investi nasal Oct s177746 ges
hydr an powder, niosomes trans gated nioso 201 han
ochl d Span 20, were derm drug mes 8 y
oride spi Span 40, develope al (NF) of abd
nal Span 80, d by thin- route was nefo elsa
cor Span 85, film succes pam yed
d choleste hydration sfully with 210
rol, PBS methodCi incorp impr 32
tablets, tation17 orated oved
acetonitr as into bioav
ile, follows: the ailabi
chlorofo accuratel core lity:
rm, y of the prep
methano weighed develo arati
l, amounts ped on,
absolute of the vesicle opti
ethanol, Spans s. The miza
and and formul tion,
formic cholester ated and
acid. ol in nioso in-
Potassiu molar mes vivo
m ratios of signific evalu
dihydrog 1:1, 1:2, antly ation
en 1:3, and impro
orthoph 1:4 of ved NF
osphate, cholester perme
sodium ol to ation
dihydrog surfactan across
en ts, nasal
phospha respectiv mucos
te, ely (Table a and
disodiu 2), were prolon
m dissolved ged
hydroge in 5 mL of the
n organic drug
phospha solvents releas
te, mixture e rate.
sodium (chlorofor In-vivo
bicarbon m: studie
ate, methanol s
sodium [2:1, showe
chloride, v/v]). The d that
calcium solvents nioso
chloride mixture mes
dehydrat was can be
e, and evaporat a
potassiu ed by promi
m Stuart sing
chloride rotary tool to
evaporat increa
or se the
(RE300) drug
equipped bioava
with ilabilit
vacuum y and
pump hence
(RE3022C reduc
; Stuart es the
Equipme requir
nt, ed
Staffords effecti
hire, UK) ve
to form a dose.
thin film The
on the obtain
inner wall ed
of the outco
flask. mes
Thin-film suppo
hydration rt our
was done theory
using PBS ,
(pH which
7.4/10 implie
mL) s that
containin intran
g 10 mg asal
of NF at deliver
55°C;Citat y of
ion18,Cit NF-
ation19 loaded
afterward nioso
, mes
niosomal can be
suspensio helpfu
ns were l in
sonicated bypass
for 1 hour ing the
 at room drug
temperat first-
ure (Ney pass
ultrasonic metab
cleaner, olism
AS 5150 and
BD, offer a
Jamestow good
n, NY, altern
USA) to ative
reduce for the
the size conve
of ntiona
produced l oral
niosomes route.
. Spans
were
chosen as
emulsifier
s as they
gave the
best thin
film after
a series
of trials
using
different
nonionic
surfactan
ts like
tweens
and brijs.
2 Curc mo Nios Curcumi This was Topic In this Prop 19 10.1016/j.apt. Ah
umin ut ome ne an in- al in- hylac Apr 2020.08.011 me
- h powder vitro and (mou vitro tic 202 d
load in-vivo thwa and effec 2 Ma
ed study. sh) in-vivo t of md
nioso Firstly, KB study, topic ouh
mes oral curcu al Ah
cancer min- (slow me
cells and loaded - d
human nioso relea 210
umbilical me se) 13
vein was and
endotheli effecti syste
al cells ve in mic
(HUVEC) preve curc
were nting umin
treated in the nano
separate develo -
groups pment nioso
with free of me
curcumin, severe antio
curcumin forms xidan
-loaded of t on
niosomes dyspla oral
, and the sia canc
unloaded and er in
niosomes the rat
at four inhibit
doses of ion of
4, 8, 16, the
and growt
32 μg. h of
The study cancer
rats were cells.
then
divided
into the
following
four
groups: 1)
no
interventi
on, 2)
only
carcinoge
nic
substance
, 3)
carcinoge
nic
substance
with
curcumin
-loaded
niosome
injection,
and 4)
carcinoge
nic
substance
with a
mouthwa
sh
 containin
g
niosome

3 l5 mu Nios Non- Oral Orall Topica 202 10.2174/1567 Nad

fluor cos ome ionic mucositis y l MNG 1 201817666200 a
oura a syntheti was potent 525151848 nab
cil c induced ially il
surfacta in ICR inhibit abd
nts such mice by s o
as 5-FU and inflam 193
sorbitan randomly matio 41
monoste assigned n and
arate to receive lipid
(Span60) daily oxidati
with the applicatio ve
addition ns of the stress
of topical in 5-
choleste oral FU-
rol MNG, a induce
fluocinolo d oral
ne mucos
acetonide itis.
gel, a
blank
niosome
gel, or no
treatmen
t for 5
days in
comparis
on with a
normal
group.
Average
body
weights,
food
consumpt
ion, and
behaviors
of the
mice as
well as
microsco
pic
histopath
 ology,
Fourier-
Transfor
m
Infrared
Spectrosc
opy (FTIR)
analysis,
proinflam
matory
cytokine
levels,
and
oxidative
stress
markers
of the
tongues
were
monitore
d and
collected
after
sacrifice

4 Pacli ca Nios Sorbitan thin-film Intra All Prep 202 10.1248/bpb.b Om

taxel nc ome monoest hydration veno nioso arati 3 23-00188 ar
er ers method us mes on Hes
cel (Span (IV) yielde and ha
ls 20, 40, d Evalu m
60, particl ation Ah
and 80), e sizes of me
sorbitan of Paclit d
triester 100– axel- 201
(Span 150 Load 18
65), nm ed
choleste which PEGy
rol, and is a lated
dicetylp benefi Nios
hosphat t for omes
e (DCP), chemo
(PEG- therap Com
DSPE) y pose
applic d of
ations Sorbi
due to tan
the
 EPR Ester
effect. s
The
PTX-
encap
sulatio
n
efficie
ncy of
Span
PEG
nioso
mes
was
much
higher
than
PTX-
loaded
liposo
mes
5 Busp Br Nios Buspiron Thin film Intra nioso Form 22 10.2174/2211 Nah
irone ain ome e evaporati nasal mes ulati Jan 738506666180 la
Hydr hydrochl on route prove on uar 130105919 kam
ochl method y al
oride(BH d the and
oride Buspiron 201 Has
) e potent Evalu 8 he
,Cholest hydrochlo ial for ation m
erol ride (BH) intran of 193
,Carbop loaded asal Nios 44
ol 934 niosomes drug omal
were
,HPMC deliver in
prepared
K4M y of situ
by thin
,Span Buspir Nasal
film
60, one Gel
evaporati
Dichloro hydroc of a
on
methane hlorid Serot
method
, o- e drug onin
[12].
phospho over Rece
Statistical
ric acid, the ptor
approach
sodium conve Agon
was used
dihydrog ntiona ist,
to
en l gel Buspi
formulate
phospha formul rone
the
te, ations. Hydr
potassiu niosomes Overal ochl
m . Batches l oride
,dihydro F1-F9 intran for
gen were asal the
phospha prepared drug Brain
te, according of Deliv
sodium to 32 deliver ery
chloride factorial y for via
along design. Buspir Intra
with Briefly, one nasal
other Span 60 hydroc Rout
chemical and hlorid e
s cholester e has
ol at the been
levels succes
indicated sfully
in Table 1 develo
were ped
dissolved
in the
10ml
dichloro
methane
Dichloro
methane
was then
removed
at 40°C
by rotary
evaporat
or to
form thin
layer on
the flask
wall. The
film was
left under
vacuum
at 50°C to
remove
the traces
 of the
organic
solvent.
The film
was
further
hydrated
with
10ml, pH
6.4
Phosphat
e buffer
solution
(PBS)
loaded
with
30mg
Buspiron
e
hydrochlo
ride.
Resultant
suspensio
n was
ultrasonic
ated to
form
multilam
ellar
niosomes

6 lacos bra Nios Span 60, Thin film Intra LCA- Nove 202 10.1016/j.ijpx. Nah
amid in ome chitosan, hydration nasal CTS- l 3 2023.100206 la
e choleste method NSM nasal sha
rol and In a formul nioso rf
lacosami nutshell, ation mes abd
de Span 60 was load alla
and create ed 193
cholester d to with 43
ol were increa lacos
mixed se amid
into reside e
chlorofor nce and
m. A durati coat
rotary on on ed
evaporat the with
or was nasal chito
used to mucos san
evaporat a,
e the physic
organic al
solvents stabilit
at a y, and
temperat bioava
ure of 55 ilabilit
°C, y of
forming a LCA in
thin film. brain
The tissues
develope .
d thin Comp
film was ared
hydrated to the
by adding LCA
10 mL solutio
phosphat n,
e LCA-
buffered CTS-
saline (pH NSM
7.4) demo
containin nstrat
g 10 mg ed a
LCA, then delaye
sonicated d
for 30 releas
min. CTS e
solution profile
was , a 2-
formulate fold
d by increa
dissolving se in
it in 1% nasal
glacial diffusi
acetic on,
acid. The increa
LCA-CTS- sed
NSM was bioava
prepared ilabilit
by adding y, and
CTS impro
solution ved
 dropwise brain
to the distrib
prepared ution
niosomal after
dispersio intran
n under asal
magnetic admini
stirring. stratio
The n.
stirring Curren
speed t
was 100 resear
rpm, and ch
the drop indicat
rate was es that
0.2 LCA-
mL/min. CTS-
The final NSM
preparati nasal
on was drops
stored in have
the the
refrigerat potent
or for ial to
subseque be
nt develo
investigat ped as
ion. a
nanopl
atform
techn
ology
for
partial
-onset
seizur
e
manag
ement
.
7 Acycl ski Nios choleste Span60/C Topic The Prep 201 10.1080/0898 Nad
ovir n ome rol or its ho/TPGS ally results arati 8 2104.2016.122 a
derivativ (55:30:15 of this on 4897 han
es, non- ) and study and y
ionic span60/C reveal evalu ha
surfacta honiosom ed ation me
nts and, eswere ACV-N of d
sometim prepared have a nioso 193
es, ionic by thin higher me 42
amphiph film antivir gel
iles. The hydration al cont
drugs, method. activit ainin
both Briefly, y g
hydrophi the lipid compa acycl
lic and mixture red ovir
hydroph consisted with for
obic, can of free enha
be cholester drug; nced
encapsul ol, span, it derm
ated in DCP or could al
the TPGS be a depo
niosome were suitabl sitio
s dissolved e n.
in carrier
chlorofor for
m and deliver
added to y of
a 250-ml acyclo
round vir in
bottom the
flask. The treatm
mixture ent of
was HSV-1
placed in infecti
a rotary ons.
vacuum
evaporat
or at 150
rpm to
evaporat
e the
solvent at
60˚C. A
thin film
of dried
lipids was
hydrated
with
solution
of
acyclovir
in
phosphat
e buffer
saline
 and
continue
d for 70
min. Then
prepared
niosomal
dispersio
n was
sonicated
at 60˚C
for 60
min.
After
sonicatio
n, the
niosomes
were
kept at
room
temperat
ure for 60
min to
form the
vesicles.
8 Doxy ski Nios Drugs, Doxycycli topic This Nios 202 10.2174/2211 Ree
cycli n ome choleste ne al study ome- 2 738510666220 m
ne rol or its hyclate dosa demo enca 224103406 Mo
derivativ was ge nstrat psula
ha
es, non- loaded form ed the ted
ionic into four ability Doxy me
surfacta niosomal of cycli d
nts and, formulati nano- ne Gho
sometim ons nioso Hycla nei
es, ionic prepared mes te m
amphiph by the contai for
193
iles thinfilm ning Pote
hydration doxyc ntiati 33
method ycline on of
with hyclat Acne
different e to Ther
percenta treat apy
ges of skin
constitue acne
nts. Drug- compa
containin red
g with
niosomal the
systems free
were drug
evaluated
for
morpholo
gical
propertie
s via
scanning
electron
microsco
py,
particle
size, drug
entrapme
nt
efficiency
, zeta
potential,
in vitro
drug
release,
physical
stability
after 60
days, in
vitro drug
permeati
on
through
rat skin,
in vitro
drug
depositio
n in rat
skin,
toxicity
on
human
dermal
fibroblast
s (HDF)
by MTT
method
after 72
hours,
and
antibacte
 rial
propertie
s against
the main
acne-
causing
bacteria
via
antibiogr
am test.
9 Celas ski Nios Niosome For the Topic Cel Celas 4 10.2147%2FIJ Had
trol n ome s which preparati al Nio trol Sep N.S323208 eer
hydr are on of Cel gel Nios 202 hes
o gel bilayer Nio, the achiev ome 1 ha
hydrated method ed the Hydr m
vesicular of thin- anti- ogel 193
systems film psoria Has 46
consistin hydration tic Anti-
g of and effect Infla
nonionic sonicatio by mma
surfacta n as inhibit tory
nts and described ing the Effec
Choleste 30 mg of inflam t on
rol , Span 20, matio Skin
Span 20 , 10 mg of n and Kerat
and Span 60, hyper inocy
Span 60 10 mg of prolife tes
cholester ration and
ol, and 2 of Circu
mg of Cel kerati latio
were nocyte n
dissolved s in with
in 4 mL of the out
chlorofor skin Syste
m. Then, and mic
cholester furthe Drug
ol was r Expo
removed suppre sure
by a ssing in
rotary the Psori
evaporat syste asis
or, and mic Mice
the dried inflam
lipid layer matio
was n, thus
hydrated could
with 5 mL be a
of Mill-Q novel
water. topical
Subseque drug
ntly, the deliver
suspensio y
n was syste
sonicated m to
with an treat
Ultrasoni psoria
c Cell sis
Crusher with
(BILON- topical
250Y, and
Shanghai) syste
at 125 W mic
with a 3- effects
mm .
probe for
2 min to
acquire
Cel Nio.
Adequate
viscosity
is
necessary
for
topical
formulati
on to
apply on
the skin.
Carbopol
was
selected
as the gel
matrix
base of
Cel
Nio.24 Bri
efly, 1%
(w/v)
Carbopol
was
added to
Cel Nio
solution
and
constantl
 y stirred
in
darkness
overnight
, then
neutralize
d with
triethanol
amine.
1 Timo Ey Nios Timolol prepared Topic Timolo Deve 23 https://doi.org/ Bas
0 lol e ome maleate, by thin al, l lopm Jan 10.1007/s40005 sant
carboxy film parti malea ent uar -019-00427-1 Mo
methylc hydration cularl te and y ha
ellulose, method , y loaded inves 201 me
span 20 where a opht Nioso tigati 9 d
,span 40, mixture halm mes on of 192
tween of non- ic were timol 36
20 ionic prepar ol
,tween surfactan ed by male
80 t and thin ate
Chlorofo cholester film nioso
rm ol in hydrat mal
,Carbop different ion form
ol934 molar metho ulati
,Trietha ratios d ons
nolami was using for
ne dissolved a the
in 10ml series treat
chlorofor of ment
m in surfact of
100ml ants glauc
rounded- (Span oma
bottom 20, 40
flask. The and
organic 60)
solvent and
was co-
removed surfact
at 60°C ants
under (Twee
reduced n 20
pres-sure and
on a Tween
rotary 40)
evaporat with
or (Bibby, choles
Model R terol.
E 200, F6
UK) at (conta
100rpm ining
to form a span
thin film 60:cho
on the lester
flask wall. ol in
The molar
excess ratio
organic 160:60
solvent ) and
was then F7
removed (conta
by leaving ining
the flask span
in a 60:tw
desiccato een
r under 40:cho
vacuum lester
overnight ol in
. The molar
obtained ratio
dried lipid 80:80:
film was 60)
diluted showe
with 10ml d the
of best
phosphat entrap
e buffer ment
solu-tion efficie
(PBS, pH ncy
7.4) and
containin perce
g timolol nt
maleate drug
(1.5mg/m releas
l) by ed
shaking within
with a 8h.
mechanic Then,
al shaker F6 and
(Gallent F7
kamp, were
England), incorp
in water orated
bath at into
60°C for carbo
about 1 h pol
with 934
gentle and
agitation CMC
to form a Na
niosomal gels at
dispersio differe
n with nt
milky conce
appear- ntratio
ance ns.
(Sammou Nioso
r et al. mal
2013). gel
The formul
resulting ations
multilam gave
ellar sustai
vesicle ned
dispersio and
n was contro
then left lled
to cool releas
for e of
separatio drug
n of the than
un- the
entrappe non
d drug nioso
mal
gels.
GN5
and
GN6
(nioso
mal
gel
prepar
ations
contai
ning
3%
CMC
Na
w/w
prepar
ed
from
nioso
mal
formul
ations
F6 and
F7
respec
tively)
showe
d
higher
stabilit
y as
they
exhibit
ed
t90
values
of
78.05
and
87.6
days,
gave
higher
AUC
than
that
be
given
by
mar-
keted
timog
el and
increa
sed
the
bioava
ilabilit
y of
Timolo
l
Malea
te by
1.5–
1.6
times
than
 marke
ted
timog
el
1 Anti No Nios Niosome The Not Nioso Jour 202 10.1007/s1105 Yas
1 micr t ome s consist research speci mes nal 2 1-022-05637- min
obial sp s of lipid involved fied demo of 71 e
s eci (no bilayers. encapsula nstrat Nano Yahi
fie nion The ting ed parti aO
d ic physicoc antimicro signific cle mar
surf hemical bials in antly Rese 193
acta characte niosomes higher arch 01
nt ristics of . antimi
vesi niosome Specific crobial
cles s vary preparati efficac
) based on on y
the non- methods compa
ionic were not red to
surfacta detailed free
nt used. in the drugs.
available Toxicit
informati y
on. reduct
ion
was
also
observ
ed.
Nioso
me-
based
nano
medici
nes
show
promi
se in
enhan
cing
therap
eutic
efficac
y and
reduci
ng
drug
 toxicit
y.
1
2